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1,3-Benzothiazole-2-yl-
hydrazones.Abstract A series of 1,3-benzothiazole-2-yl-hydrazones were synthesized and evaluated for anti-
bacterial activity against four different bacterial species and antifungal activity against two different
fungal species by disk diffusion method displaying different degree of antimicrobial activity. All the
synthesized compounds were in good agreement with elemental and spectral data (FT-IR, 1H NMR
and mass spectroscopy). In vitro antimicrobial activity was evaluated against the four pathogenic
bacterial strains, Bacillus subtilis, Escherichia coli, Klebsiella pneumoniae and Pseudomonas alkalig-
enes and three fungal strains Aspergillus niger, Rhizopus oryzae and Candida albicans. The com-
pounds have shown moderate activity. Compounds 3a and 3b were found to be most active.
ª 2011 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
The rapid emergence of multidrug resistant pathogenic bac-
teria has become a serious health threat worldwide. It has
been postulated that the development of resistance to known
antibiotics could be overcome by identifying new drug tar-
gets via genomics, improving existing antibiotics and by
identifying new antibacterial agents with novel structure
and mode of action (Walsh, 2000; Ritter and Wong,2001). Since in the last two decades the incidence of invasive
fungal infections has risen sharply, it has become imperative
to enlarge the number of antifungal drugs with more potent
activity and less toxicity (Maertens and Boogaerts, 2005;
Datry and Bart-Delabesse, 2006). In order to gain new in-
sights into the complexity of the disease, robust screening
methods for evaluating different natural or synthetic drugs
have been carried out from the science community. In this
respect, the benzothiazole constitutes an important scaffold
of drugs, possessing several pharmacological functions, ren-
dering this molecule and its derivatives powerful antitumour
agents (Leong et al., 2004; Yldiz-Oren et al., 2004; Lochart
et al., 2005), neurotransmission blocker (Benavides et al.,
1985; Mizoule et al., 1985), antimicrobial and antifungal
activities as well as used as b-amyloid imaging agents
(Quiroga et al., 2002; Kok et al., 2007). Recently, structur-
ally novel benzothiazole derivatives have been shown to
496 V. Asati et al.have improved biological activity. Some of the 2-amino
derivatives have been reported to possess antimicrobial
activities.
Benzothiazole and its derivatives represent the types of
compounds with versatility for their utilization. They contain
extended p-delocalized systems which are capable of binding
to DNA molecules via p–p interactions and therefore exhibit
complex biological properties, for instance antitumor, anti-
infective, antifungal or antihelmintic activities (Pavlovic
et al., 2007).
Benzothiazole derivatives in recent years have acquired
conspicuous signiﬁcance due to their wide spectrum of biolog-
ical activities and hence the present study was undertaken in
order to synthesize some new compounds having this nucleus
with the hope to enhance the biological properties of the newly
designed compounds with substitution on 2 and 6 position of
heterocyclic ring. Therefore, a study was initiated to explore
the activity of this class of compound. The present work re-
ports the synthesis of some new 1,3-benzothiazole-2-yl-hydra-
zone derivatives and their in vitro antibacterial and antifungal
screening as a part of our program aimed at the development
of new heterocyclic compounds with potential antimicrobial
activities.
2. Experimental
The purity of the synthesized compounds were ascertained by
thin layer chromatography on silica gel G in various solvent sys-
tems using iodine vapours as detecting agent. Melting points
were determined by the melting point determination apparatus
in open capillary tubes and are uncorrected. Elemental analyses
were done using Carlo Erba 1106CHNAnalyzer. Infrared spec-
tra were recorded on Perkin–Elmer Spectrum RXI FTIR spec-
trophotometer in KBr phase. Proton NMR spectra were
recordedonBrukerAvance II 400NMRUltra Shield Spectrom-
eter usingDMSO-d6 as a solvent and tetramethyl silane as inter-
nal standard. Chemical shift value is expressed in delta parts per
million (ppm). All chemicals and reagents were obtained from
Aldrich (USA) and SpectrochemPvt. Ltd. (India) andwere used
without further puriﬁcation.
2.1. Chemistry
6-Chloro-2-benzothiazolamine was synthesized by interaction
of p-chloroaniline with potassium thiocyanate in the presenceTable 1 Physical data of synthesized compounds.
Compound R1 R2 Colour Me
1 – – Yellowish 160
2 – – Light grey 220
3a CH3 NO2 Yellowish 280
3b CH3 Br Gray 220
3c CH3 OCH3 Light brown 230
3d CH3 Cl Light brown 213
3e CH3 OH Brown 225
3f CH3 NH2 Yellowish white 234
3g C6H5 H Brown 190
3h CH3 H White 180
3i H F Creamish brown 230
3j H CH3 Light gray 220of bromine. 2-Benzothiazolamine was then reﬂuxed with
hydrazine hydrate to yield hydrazine derivative, 6-chloro-2-
benzothiazol-2-yl-hydrazine. The ﬁnal compounds (1,3-benzo-
thiazole-2-yl-hydrazones) were synthesized by the reaction of
hydrazine benzothiazole with appropriate ketones and
aldehydes.
2.2. General method
The title compounds were prepared in following steps:
2.2.1. Synthesis of 6-chloro-2-benzothiazolamine (1)
p-Chloroaniline (0.01 mol) and potassium thiocyanate
(0.08 mol) were dissolved in glacial acetic acid (20 mL), cooled
and stirred for 15 min at 2–4 C. Cold bromine solution
(0.01 mol, 1.6 mL in 6 mLacetic acid)was added dropwise. Stir-
ring was continued for 2 h and then at room temperature for
10 h. Separated hydrochloride salt was ﬁltered off, washed with
acetic acid, dissolved in hot water and neutralized with aqueous
ammonia solution (25%) The resulting precipitate was ﬁltered
off, washed with water and recrystallized from ethanol.
2.2.2. Synthesis of 6-chloro-2-benzothiazol-2-yl-hydrazine (2)
With stirring to hydrazine hydrate (99%, 6 mL) solution conc.
HCl (6 mL) was added drop wise at 5–10 C temperature. To it
ethylene glycol (24 mL) and compound (1) (0.03 mol) were
added in portion and reﬂuxed for 3 h. Reaction mixture cooled
to room temperature and was poured to crushed ice to afford a
solid which was ﬁltered and recrystallized from ethanol to yield
compound 2.
2.2.3. Synthesis of 1-(4-substituted phenyl) ethanone (6-chloro-
1,3-benzothiazol-2-yl) hydrazone (3a–3b)
The solution of compound (2, 1.5 mmol) in glacial acetic acid
(5 mL) and ethanol (20 mL) was heated to boiling and reﬂuxed
with appropriate aromatic ketones (2.2 mmol) for 5 h. The
reaction mixture was cooled to room temperature and kept
overnight. The solid separated was collected out, washed with
methanol, dried and recrystallized from ethanol to get the pure
ﬁnal compound.
By adopting similar type of procedures, 10 compounds
were synthesized. Physical and analytical data of synthesized
compounds is given in Table 1. Synthetic pathway for prepara-
tion of title compounds is shown in Scheme 1.lting point (C) Yield (%) Rf value
–163 81 0.66 (benzene/acetone 8:2)
–223 83 0.66 (benzene/acetone 8:2)
–283 74 0.79 (CHCl3/CH3OH 9.5:0.5)
–225 78 0.76 (benzene/acetone 9:1)
–235 75 0.71 (benzene/acetone 8:2)
–215 78 0.82 (benzene/acetone 9:1)
–228 81 0.79 (benzene/acetone 9:1)
–238 76 0.78 (CHCl3/CH3OH 8.5:1.5)
–193 73 0.74 (CHCl3/CH3OH 8.5:1.5)
–183 74 0.81 (CHCl3/CH3OH 9.5:0.5)
–233 76 0.83 (Benzene/CHCl3 8:2)
–224 78 0.76 (benzene/acetone 8:2)
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Scheme 1 Reagents and conditions: (i) CH3COOH, KSCN,
BR2, stirring 10 h; (ii) NH2NH2ÆH2O, ethylene glycol, reﬂux 3 h;
(iii) ethanol, reﬂux 5 h.
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2.3.1. 6-Chloro-2-benzothiazolamine (1)
IR (KBr, cm1): 3417 (NH), 3086 (CH-Ar), 1512 (C‚N), 1263,
1280 (C–N), 1082 (C–Cl), 615 (C–S–C). 1H NMR (300 MHz,
DMSO-d6, d ppm): 7.12 (m, 7H, Ar-H), 7.10
(s, 1H,NHN–,D2O exchangeable).Anal. Calcd. forC9H8ClNS:
C, 52.32; H, 3.29; N, 7.63. Found: C, 51.87; H, 3.30; N, 7.60.
2.3.2. 6-Chloro-2-benzothiazol-2-yl-hydrazine (2)
IR (KBr, cm1): 3484 (NH), 3084 (CH-Ar), 1548 (C‚N), 1257
(C–N), 1112 (C–Cl), 604 (C–S–C). 1H NMR (300 MHz,
DMSO-d6, d ppm): 7.87 (m, 7H, Ar-H), 4.0 (s, 1H, NHN–,
D2O exchangeable). Anal. Calcd. for C8H7ClN2S: C, 48.36;
H, 3.55; N, 14.10. Found: C, 48.87; H, 3.36; N, 15.6.
2.3.3. 1-(4-Nitrophenyl)ethanone(6-chloro-1,3-benzothiazol-2-
yl) hydrazone (3a)
IR (KBr, cm1): 3321 (NH), 3119 (CH-Ar), 2879, 2962 (CH-
Aliph.), 1554 (C‚N), 1452, 1336 (Ar C–NO2), 1257 (C–N),
964 (C–Cl), 719 (C–S–C). 1H NMR (300 MHz, DMSO-d6, d
ppm): 0.9 (s, 3H, CH3), 8.14–7.16 (m, 7H, Ar-H), 7.13 (s,
1H, NHN–, D2O exchangeable). Anal. Calcd. for
C15H11ClN4O2S: C, 51.95; H, 3.20; N, 16.6. Found: C,
51.87; H, 3.30; N, 15.6.
2.3.4. 1-(4-Bromophenyl)ethanone(6-chloro-1,3-benzothiazol-2-
yl) hydrazone (3b)
IR (KBr, cm1): 3253 (NH), 3082 (CH-Ar), 2951, 2845 (CH-
Aliph.), 1558 (C‚N), 1263 (C–N), 1005 (C–Cl), 663 (C–S–
C), 559 (C–Br), 1H NMR (300 MHz, DMSO-d6, d ppm): 1.2
(s, 3H, CH3), 8.04–7.16 (m, 7H, Ar-H), 7.56 (s, 1H, NHN–,
D2O exchangeable). Anal. Calcd. for C15H11BrClN3S: C,
47.32; H, 2.91; N, 11.4. Found: C, 47.45; H, 3.10; N, 11.2.
2.3.5. 1-(4-Methoxyphenyl)ethanone(6-chloro-1,3-
benzothiazol-2-yl) hydrazone (3c)
IR (KBr, cm1): 3207 (NH), 3070 (CH-Ar), 2953, 2835 (CH-
Aliph.), 1550 (C‚N), 1255 (C–N), 1035 (C–Cl), 713(C–S–C). 1H NMR (300 MHz, DMSO-d6, d ppm): 1.07 (s,
3H, CH3), 8.06–7.08, 6.87 (m, 7H, Ar-H), 3.754 (s, 1H, Ar-
OH), 7.08 (s, 1H, NHN–, D2O exchangeable). Anal. Calcd.
for C16H14ClN3OS: C, 57.91; H, 4.25; N, 12.66. Found: C,
57.45; H, 4.10; N, 12.24.
2.3.6. 1-(4-Chlorophenyl)ethanone(6-chloro-1,3-benzothiazol-
2-yl) hydrazone (3d)
IR (KBr, cm1): 3314 (NH), 3084 (CH-Ar), 2949 (CH-Aliph.),
1548 (C‚N), 1257 (C–N), 1112 (C–Cl), 688 (C–S–C). 1H
NMR (300 MHz, DMSO-d6, d ppm): 0.86 (s, 3H, CH3),
8.04–7.16 (m, 7H, Ar-H), 7.13 (s, 1H, NHN–, D2O exchange-
able). Anal. Calcd. for C15H11Cl2N3S: C, 53.54; H, 3.43; N,
12.66. Found: C, 53.45; H, 3.10; N, 12.24.
2.3.7. 1-(4-Hydroxyphenyl)ethanone(6-chloro-1,3-
benzothiazol-2-yl) hydrazone (3e)
IR (KBr, cm1): 3309 (OH), 3042 (CH-Ar), 2981, 2805 (CH-
Aliph.), 1558 (C‚N), 1267 (C–N), 1114 (N–N), 1068 (C–Cl),
578 (C–S–C). 1H NMR (300 MHz, DMSO-d6, d ppm): 0.91
(s, 3H, CH3), 8.34–7.45 (m, 7H, Ar-H), 5.0 (s, 1H, Ar-OH),
7.12 (s, 1H, NHN–, D2O exchangeable). Anal. Calcd. for
C15H12ClN3OS: C, 56.69; H, 3.81; N, 13.22. Found: C,
57.36; H, 3.27; N, 12.24.
2.3.8. 1-(4-Aminophenyl)ethanone(6-chloro-1,3-benzothiazol-2-
yl) hydrazone (3f)
IR (KBr, cm1): 3489–3308 (NH), 3090 (CH-Ar), 2962 (CH-
Aliph.), 1558 (C‚N), 1294 (C–N), 1064 (C–Cl), 808 (C–S–C).
1H NMR (300 MHz, DMSO-d6, d ppm): 0.97 (s, 3H, CH3),
7.934–7.302 (m, 7H, Ar-H), 3.186 (s, 2H, Ar C–NH), 7.17 (s,
1H,NHN–,D2O exchangeable). Anal. Calcd. forC15H13ClN4S:
C, 56.87; H, 4.14; N, 17.68. Found: C, 56.35; H, 4.54; N, 16.24.
2.3.9. Diphenylmethanone(6-chloro-1,3-benzothiazol-2-
yl)hydrazone (3g)
IR (KBr, cm1): 3301 (NH), 3016 (CH-Ar), 1494 (C‚N), 1288
(C–N), 1016 (C–Cl), 653 (C–S–C). 1H NMR (300 MHz,
DMSO-d6, d ppm): 8.17–6.7 (m, 7H, Ar-H), 7.0 (s, 1H,
NHN–, D2O exchangeable). Anal. Calcd. for C20H14ClN3S:
C, 66.02; H, 3.88; N, 11.55. Found: C, 66.35; H, 4.54; N, 12.24.
2.3.10. 1-Phenylethanone(6-chloro-1,3-benzothiazol-2-
yl)hydrazone (3h)
IR (KBr, cm1): 3306 (NH), 3090 (CH-Ar), 2947 (CH-Aliph.),
1550 (C‚N), 1257 (C–N), 1107 (C–Cl). 1H NMR (300 MHz,
DMSO-d6, d ppm): 1.15 (s, 3H, CH3), 7.86–6.7 (m, 7H, Ar-H),
7.11 (s, 1H, NHN–, D2O exchangeable). Anal. Calcd. for
C15H12ClN3S: C, 59.70; H, 4.01; N, 13.92. Found: C, 59.35;
H, 4.54; N, 12.24.
2.3.11. 4-Fluorobenzaldehyde(6-chloro-1,3-benzothiazol-2-yl)
hydrazone (3i)
IR (KBr, cm1): 3309 (NH), 3039 (CH-Ar), 2949 (CH-Aliph.),
1570 (C‚N), 1267 (C–N), 1124 (C–F), 1089 (C–Cl), 580 (C–S–
C). 1H NMR (300 MHz, DMSO-d6, d ppm): 8.027 (s, 1H,
Ar CH‚N), 7.962–7.059 (m, 7H, Ar-H), 3.947 (s, 1H,
NHN–, D2O exchangeable). Anal. Calcd. for C14H9ClFN3S:
C, 54.99; H, 2.97; N, 13.74. Found: C, 54.35; H, 2.54; N, 12.87.
Table 2 In vitro antibacterial activity of the title compounds (3a–j).
Compound Conc. (lg/
mL)
Zone of inhibition (mm)
E. coli
[MTCC 43]
B. subtilis [MTCC
441]
K. pneumoniae
[MTCC 432]
P. alkaligenes
[MTCC 493]
3a 50 – 18.5 – 9.0
100 – 19.0 – 9.0
3b 50 – 11.2 – 7.0
100 – 23.2 – 10.0
3c 50 – – 9.1 8.0
100 8.0 – 10.9 11.0
3d 50 – 7.0 9.0 8.0
100 – 7.0 9.0 12.0
3e 50 – 7.0 8.0 7.0
100 – 7.5 9.0 8.0
3f 50 – 7.0 8.0 –
100 – 8.5 9.0 –
3g 50 – 7.0 – 8.0
100 – 7.5 – 8.0
3h 50 – 7.0 – 8.0
100 – 7.5 – 8.0
3i 50 – 7.0 9.0 –
100 – 9.0 9.0 –
3j 50 – 9.0 8.0 –
100 – 13.0 9.0 –
Control (DMF) 50 – – – –
100 – – – –
Norﬂoxacin
(standard drug)
50 16 24 18 19
100 18 25 20 20
Table 3 In vitro antifungal activity of the title compoundsa
(3a–j).
Compound Zone of inhibition (in mm)
C. albicans
[MTCC-183]
R. oryzae
[MTCC-262]
A. niger
[MTCC-554]
3a ++ ++ +
3b ++ + +
3c + + 
3d  ± ±
3e   
3f   
3g   
3h   
3i ±  
3j ±  ±
Ketoconazole
(standard drug)
++ ++ ++
DMF
(control)
  
++: no growth, no fungal colony (highly active).
+: 0–20% growth, 1–2 fungal colony (active).
±: 20–40 growth, 2–4 fungal colony (moderately active).
: >40% growth, more than four fungal colonies (no activity).
a Concentration: 100 lg/mL.
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hydrazone (3j)
IR (KBr, cm1): 3169 (NH), 3028 (CH-Ar), 2949 (CH-Aliph.),
1570 (C‚N), 1267 (C–N), 1072 (C–Cl), 582 (C–S–C). 1HNMR
(300 MHz, DMSO-d6, d ppm): 2.25 (s, 3H, CH3), 8.17–7.1 (m,
7H, Ar-H), 4.0 (s, 1H, NHN–, D2O exchangeable). Anal.Calcd. for C15H12ClN3S: C, 59.70; H, 4.01; N, 13.92. Found:
C, 59.98; H, 4.76; N, 12.87.
3. Antimicrobial evaluation
Antimicrobial screening of the 1,3-benzothiazole-2-yl-hydra-
zones was done following the disc diffusion technique (Grover
and Moore, 1962; Barry, 1976; Tripathi and Mishra, 2007).
All the compounds (3a–3j) were screened for their in vitro anti-
bacterial activity against Bacillus subtilis [MTCC 441], Esche-
richia coli [MTCC 43], Klebsiella pneumoniae [MTCC 432],
and Pseudomonas alkaligenes [MTCC 493] at 50 and 100 lg/
mL with Norﬂoxacin as the standard drug. Antifungal activity
was conducted against Aspergillus niger, Rhizopus oryzae and
Candida albicans at 100 lg/mL using Ketoconazole as the stan-
dard drug. The test organisms were ﬁrst cultured in nutrient
broth and incubated for 24 h at 37 C and then freshly prepared
bacterial cells and fungal spores were spread onto the Muller
Hinton agar plates and Potato Dextrose Agar medium, respec-
tively, in a laminar ﬂow cabinet. The test compoundswhichwere
previously dissolved inDMFwere then soaked onto sterile disks
of Whatman ﬁlter paper (5 mm diameter). The disks were then
placed onto the surface of the previously prepared inoculated
plates and incubated. The zone of inhibition was recorded in
mm after incubation of plates for 24 h (antibacterial) and 72 h
(antifungal) at 37 C as shown in Tables 2 and 3.4. Results and discussion
The synthesis of 1-(4-substituted phenyl) ethanone (6-chloro-
1,3-benzothiazol-2-yl) hydrazone (3a–j) was accomplished as
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amine and formation of compound 1, through KSCN then
involves the reaction of hydrazine hydrate with compound 1
in the presence of ethylene glycol and ﬁnally formation of
the compounds (3a–j) through reaction of substituted ketones
in the presence of ethanol and compound 2 by reﬂuxing for
6 h. Synthesized compounds were characterized by elemental
analysis, FT-IR, and 1H NMR spectrum. The FT-IR spectrum
exhibited characteristic bands for NH, CH-Ar and C‚N at
3484–3306, 3090–3016 and 1568–1512 cm1. The 1H NMR
spectrum showed singlet at d 1.146–0.905 conﬁrmed N‚C–
CH3, multiplets ranging from d 8.12–6.86, conﬁrmed aromatic
protons and singlet ranges at d 7.17–6.057 conﬁrmed the pres-
ence of NHN–, respectively, which were D2O exchangeable.
The synthesized compounds were evaluated for their anti-bac-
terial activity against B. subtilis, E. coli, K. pneumoniae
and P. alkaligenes and anti-fungal activity against A. niger,
C. albicans, and R. oryzae. Compounds 3a and 3b showed
maximum activity (18–23 mm) zone size against B. subtilis
due to substitution of electron donating group (i.e. CH3) on
R1 position and electron withdrawing group (i.e. NO2, Br)
on R2 position while all other compounds showed moderate
activity. Compound 3a and 3b were also found to have good
activity against A. niger and C. albicans.Acknowledgements
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